Skip to main content
Top
Published in: Osteoporosis International 2/2014

01-02-2014 | Case Report

Can long-term bisphosphonate use causes low-energy fractures? A case report

Authors: T. Dandinoğlu, S. Akarsu, M. Karadeniz, L. Tekin, S. Arıbal, M. Z. Kıralp

Published in: Osteoporosis International | Issue 2/2014

Login to get access

Abstract

Bisphosphonates are inorganic pyrophosphate analog which accumulate on the bone surface, cause osteoclast apoptosis, and inhibit bone resorption. The nitrogen-containing bisphosphonates continue to be the drug of choice for the treatment of osteoporosis in both men and women. Although histomorphometric studies including bone biopsies have not shown any evidence of microcracks, recent studies have revealed that potent bisphosphonates are responsible for the oversuppression of bone turnover leading to microdamages, reduced bone strength, and increased fracture risk. There are individual cases reporting atypical femoral fractures and severely suppressed bone turnover along with long-term (≥5 years) use of biphosphonates. In this study, we report on a 74-year-old woman with a history of continuous alendronate use for nearly 16 years who presented to the emergency department with right proximal humerus and left femur fracture.
Literature
1.
go back to reference Bartl R, Frisch B (2009) Osteoporosis diagnosis, prevention, therapy, 2nd edn. Springer, Berlin Bartl R, Frisch B (2009) Osteoporosis diagnosis, prevention, therapy, 2nd edn. Springer, Berlin
2.
go back to reference Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef
3.
go back to reference Mashiba T, Turner CH, Hirano T et al (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28(5):524–531PubMedCrossRef Mashiba T, Turner CH, Hirano T et al (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28(5):524–531PubMedCrossRef
4.
go back to reference Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362PubMedCrossRef Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362PubMedCrossRef
5.
go back to reference Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32(9):775–785PubMedCrossRef Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32(9):775–785PubMedCrossRef
6.
go back to reference Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189–1199PubMedCrossRef Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189–1199PubMedCrossRef
7.
go back to reference Ste-Marie LG, Sod E, Johnson T et al (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75(6):469PubMedCrossRef Ste-Marie LG, Sod E, Johnson T et al (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75(6):469PubMedCrossRef
8.
go back to reference Chapurlat RD, Arlot M, Burt-Pichat B et al (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22(10):1502–1509PubMedCrossRef Chapurlat RD, Arlot M, Burt-Pichat B et al (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22(10):1502–1509PubMedCrossRef
9.
go back to reference Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69(5):281–286PubMedCrossRef Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69(5):281–286PubMedCrossRef
10.
go back to reference Mashiba T, Hui S, Turner CH et al (2005) Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 77(3):180–185PubMedCrossRef Mashiba T, Hui S, Turner CH et al (2005) Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 77(3):180–185PubMedCrossRef
11.
go back to reference Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef
12.
go back to reference Kwek EB, Goh SK, Koh JS et al (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef Kwek EB, Goh SK, Koh JS et al (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef
13.
go back to reference Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24(6):1095PubMedCrossRef Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24(6):1095PubMedCrossRef
14.
go back to reference Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783PubMedCrossRef Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783PubMedCrossRef
15.
go back to reference Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267PubMedCrossRef Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267PubMedCrossRef
16.
go back to reference Tang ZH, Kumar VP (2011) Alendronate-associated ulnar and tibial fractures: a case report. J Orthop Surg Hong Kong 19(3):370–372PubMed Tang ZH, Kumar VP (2011) Alendronate-associated ulnar and tibial fractures: a case report. J Orthop Surg Hong Kong 19(3):370–372PubMed
17.
go back to reference Bauer DC, Garnero P, Hochberg MC et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21(2):292–299PubMedCrossRef Bauer DC, Garnero P, Hochberg MC et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21(2):292–299PubMedCrossRef
Metadata
Title
Can long-term bisphosphonate use causes low-energy fractures? A case report
Authors
T. Dandinoğlu
S. Akarsu
M. Karadeniz
L. Tekin
S. Arıbal
M. Z. Kıralp
Publication date
01-02-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 2/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2428-0

Other articles of this Issue 2/2014

Osteoporosis International 2/2014 Go to the issue